Is Effexor affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2D6

Considering GeneSight for Effexor?

Gene2Rx covers this medication using the same CPIC and FDA guidelines GeneSight uses, costs $5-$49 instead of several hundred, and works with your existing 23andMe data. Already have a GeneSight report? Use your GeneSight results.

See the comparison →

Effexor is affected by pharmacogenetics through the CYP2D6 gene. Your genotype for this gene can change how your body processes Effexor, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Effexor

venlafaxine affected by CYP2D6

Affected by CYP2D6 · CPIC, FDA · Strong evidence

Read the full venlafaxine genetics guide →

Venlafaxine phenotype recommendations

Published guidance from CPIC and FDA on how venlafaxine should be dosed or substituted based on your CYP2D6 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2D6	Your body may process this drug faster than usual, but no change in dose is currently recommended.	CPIC No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects. FDA Initiate therapy with recommended starting dose.	Optional
Normal Metabolizer CYP2D6	Your body is expected to process this drug normally; standard dosing is recommended.	CPIC + FDA Initiate therapy with recommended starting dose.	Strong
Intermediate Metabolizer CYP2D6	Your body may process this drug a bit slower, but no change in dose is currently recommended.	CPIC No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects. FDA Initiate therapy with recommended starting dose.	Optional
Poor Metabolizer CYP2D6	Your body processes this drug much more slowly, so an alternative medication may be safer.	CPIC Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2D6. FDA Consider a lower dose. Your body breaks down venlafaxine much more slowly, leading to higher drug levels.	Moderate
Indeterminate CYP2D6	The impact of your genotype on response to this drug is unknown.	CPIC No recommendation. FDA Initiate therapy with recommended starting dose.	—
Not available CYP2D6	The impact of your genotype on response to this drug is unknown.	CPIC No recommendation. FDA Initiate therapy with recommended starting dose.	—

Sources: CPIC, FDA

The gene behind the guidance

CYP2D6 Cytochrome P450 2D6

CYP2D6 is the most clinically important pharmacogene. It metabolizes around a quarter of all prescription drugs, including many antidepressants, opioids, and stimulants. The gene is unusually variable: roughly 7 percent of people are poor metabolizers (they barely activate CYP2D6), and another 1 to 3 percent are ultrarapid metabolizers (their enzyme is overactive).

The v4 report preserves the activity score used in its interpretation. Some medicines use a combined CYP2D6/CYP2C19 recommendation. CYP2D6 inhibitors can change functional metabolism; a genotype alone does not capture that effect.

See all drugs affected by CYP2D6 →

Related medications

Find out how your genetics affect Effexor

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.